Abstract
In responding to the opioid crisis, the FDA needs to recognize shifting trends in the addiction landscape. Taking a systematic approach to monitoring such trends should allow the agency to intervene promptly and appropriately to protect the public from associated risks.
Cite
CITATION STYLE
APA
Throckmorton, D. C., Gottlieb, S., & Woodcock, J. (2018). The FDA and the Next Wave of Drug Abuse — Proactive Pharmacovigilance. New England Journal of Medicine, 379(3), 205–207. https://doi.org/10.1056/nejmp1806486
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free